Rituxan®
What is Rituxan®?
Rituxan® (rituximab) is a monoclonal antibody used to treat autoimmune diseases and certain types of blood cancers by targeting CD20, a protein found on B-cells. By binding to CD20, Rituxan® marks B-cells for destruction by the immune system, helping to reduce inflammation and abnormal immune responses in autoimmune diseases, while also depleting cancerous B-cells in blood cancers.
How does Rituxan® work?
Rituxan® targets and eliminates CD20-positive B-cells, which play a role in autoimmune diseases and blood cancers. It also helps to reduce inflammation and immune system overactivity in autoimmune conditions. Rituxan® can slow disease progression and improve symptoms in both cancer and immune-mediated disorders.
How much does Rituxan® cost?
Rituxan® cost can vary depending on several factors including insurance status and insurance provider. Our team at Rocky Mountain MS Clinic are committed to lowering costs and improving access for our patients.
We work with virtually all leading commercial insurance providers in the greater Intermountain region, including Aetna, Anthem, Blue Cross Blue Shield, Cigna, DMBA, EMI Health, Humana, PEHP Health & Benefits, Select Health, as Tricare, as well as Medicaid and Medicare.
We’re here to make treatment more affordable and less stressful. Our team takes care of prior authorizations and benefits verification for you, and we’ll personally guide you through copay assistance and foundation support programs to help lower your out-of-pocket costs.
Why Patients Choose Rocky Mountain Infusion Center to Receive Their Rituxan® Infusion:
Clinical Excellence and Neurological Expertise
Our infusion center is proud to have a board-certified neurologist on-site, along with a team of BSN-prepared and Multiple Sclerosis-certified Registered Nurses, all committed to delivering the highest standard of care for our patients.
Lower Costs and Financial Assistance
We handle prior-authorization, benefits verification, and guide patients through copay assistance and foundation programs to reduce out-of-pocket costs. Additional financial help may be available if you qualify — just ask, and we’ll help you explore every option.
A Cigna report recently found that with a physician-owned infusion site, like RMMSC’s Infusion Center, patients see much lower out-of-pocket and overall costs than they would at a hospital outpatient infusion center.
Established leader in MS & Neurological care
35+ years in the Intermountain region, serving thousands of individuals with MS and other neurological disorders.
The infusion clinic nurses are highly trained in Neurological conditions, personable, professional and careful. Having a doctor and team like this on your side of the fight against MS is invaluable.
They are constantly improving their in-house infusion center to ensure the comfort of their patients. The team there is professional and highly trained!
As someone who frequents their infusion center on a monthly basis, I can confidently say that it's top-notch. The staff at the infusion center are amazing, providing not only excellent medical care but also creating a comfortable and soothing environment for patients. Their dedication to patient comfort and well-being is evident in every aspect of the center.
Important Info
Non-Hodgkin’s Lymphoma (NHL)
B-cell acute leukemia (B-AL)
Chronic Lymphocytic Leukemia (CLL)
Rheumatoid arthritis (RA)
Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis)
Microscopic Polyangiitis (MPA)
Pemphigus Vulgaris (PV)
Non-Hodgkin’s Lymphoma (NHL): Approved on November 26, 1997
B-cell acute leukemia (B-AL): Approved on February 10, 2006
Chronic Lymphocytic Leukemia (CLL): Approved on February 19, 2010
Rheumatoid arthritis (RA): Approved on February 28, 2006
Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis): Approved on September 27, 2019
Microscopic Polyangiitis (MPA): Approved on September 27, 2019
Pemphigus Vulgaris (PV): Approved on June 7, 2018
Genentech